Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

Sickle Cell Disease Clinical Trial

Official title:

Pilot Study to Investigate the Use of Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06184126
• Other study ID #: HP-00106992
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2024
• Source: University of Maryland, Baltimore
• Contact: R. Gentry Wilkerson, MD
• Phone: 410-328-4237
• Email: gwilkerson[@]som.umaryland.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.

Description:

A prospective, non-blinded, non-randomized trial will be conducted at the Adult Emergency Department at the University of Maryland Medical Center and Adult Urgent Care Center, which is managed by the Department of Emergency Medicine, located in Baltimore, Maryland.

Patients meeting eligibility criteria and who have signed the research informed consent will be enrolled in this study. Subject data collected will include demographic information, symptoms of the current illness and physical exam findings.

Upon enrollment into the study, a study team member will interview the patient to collect data needed to complete the Case Report Form. Patients assigned to one of the two virtual reality study groups will be directed by research coordinators who can help with equipment as needed throughout the session. The virtual reality device will be limited to a maximum of 2 hours of use. Assessments will be made at 4 different timepoints: 1) Immediately before the intervention, 2) at the 1-hour mark of the intervention, 3) immediately after the intervention, and 4) 1 hour after the intervention. During these assessments, patients will rate their pain intensity using a 0-10 numerical scale. Additionally, at each assessment, patients will be asked to state the change in pain that has taken place since the last measurement. This measurement will be performed without informing the patient of their previously recorded pain scores.

Data will also be recorded regarding the patient's 1) comfort of the device, 2) disposition (discharged home vs observation/admission status), 3) total length of treatment time in the ED (measured as time to initiation of any treatment to the time of final disposition), and 4) total amount of opioids administered while under the care of the emergency department clinicians, converted into morphine milligram equivalents. Each patient will complete a questionnaire at the conclusion of the session regarding their perceived impact of the intervention, ease of use, and likelihood to reuse the intervention.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 31, 2025
• Est. primary completion date: September 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult (age > 18 years) emergency department patient

• History of sickle cell disease

• Presenting to the emergency department due to acute pain related to sickle cell disease thought to be due to vaso-occlusive crisis

Exclusion Criteria:

• Prior enrollment in this study

• Presenting with a chief complaint suggestive of a complicated crisis (such as concern for acute chest syndrome, splenic sequestration, hepatic sequestration, pulmonary embolism) as determined by the clinical care provider

• Not being treated with intravenous opioids for the vaso-occlusive crisis

• Patients who lack the capacity to provide informed consent

• Medical history of seizures or known intolerance to virtual reality

• Disabilities like vision and hearing defects etc. that preclude the use of a head mounted virtual reality device.

• Known to be pregnant

• Incarcerated at the time of evaluation

• Over the age of 89 years old

Related Conditions & MeSH terms

• Acute Pain
• Anemia, Sickle Cell
• Sickle Cell Disease
• Vaso-occlusive Pain Episode in Sickle Cell Disease

Intervention

Device:
• Virtual Reality Headset and Hand-Held Controllers
Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.

Other:
• Blindfolding and Noise Cancelling
Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.

Locations

Country	Name	City	State
United States	University of Maryland Medical Systems	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

References & Publications (9)

Agrawal AK, Robertson S, Litwin L, Tringale E, Treadwell M, Hoppe C, Marsh A. Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatr Blood Cancer. 2019 Feb;66(2):e27525. doi: 10.1002/pbc.27525. Epub 2018 Oct 26. — View Citation

Chuan A, Zhou JJ, Hou RM, Stevens CJ, Bogdanovych A. Virtual reality for acute and chronic pain management in adult patients: a narrative review. Anaesthesia. 2021 May;76(5):695-704. doi: 10.1111/anae.15202. Epub 2020 Jul 27. — View Citation

Duroseau Y, Beenhouwer D, Broder MS, Brown B, Brown T, Gibbs SN, Jackson K, Liang S, Malloy M, Romney ML, Shani D, Simon J, Yermilov I. Developing an emergency department order set to treat acute pain in sickle cell disease. J Am Coll Emerg Physicians Open. 2021 Aug 7;2(4):e12487. doi: 10.1002/emp2.12487. eCollection 2021 Aug. — View Citation

Jang T, Poplawska M, Cimpeanu E, Mo G, Dutta D, Lim SH. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021 Sep 20;19(1):397. doi: 10.1186/s12967-021-03074-z. — View Citation

Mercado SH. An outpatient pain plan and ED pain pathway for adults with sickle cell disease. JAAPA. 2023 Mar 1;36(3):20-23. doi: 10.1097/01.JAA.0000920956.33631.26. — View Citation

Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol. 2020 Sep 29;11:2040620720955000. doi: 10.1177/2040620720955000. eCollection 2020. — View Citation

Smith V, Warty RR, Sursas JA, Payne O, Nair A, Krishnan S, da Silva Costa F, Wallace EM, Vollenhoven B. The Effectiveness of Virtual Reality in Managing Acute Pain and Anxiety for Medical Inpatients: Systematic Review. J Med Internet Res. 2020 Nov 2;22(11):e17980. doi: 10.2196/17980. — View Citation

Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol. 2019 Jan 24;14:263-292. doi: 10.1146/annurev-pathmechdis-012418-012838. Epub 2018 Oct 17. — View Citation

Williams H, Tanabe P. Sickle Cell Disease: A Review of Nonpharmacological Approaches for Pain. J Pain Symptom Manage. 2016 Feb;51(2):163-77. doi: 10.1016/j.jpainsymman.2015.10.017. Epub 2015 Nov 17. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of the change in pain scores between the 3 groups at one hour after completion of the study intervention.	Patient reported on 0-10 scale	A single time point 1 hour after the study intervention ends.
Secondary	Comparison of the subject's assessment of comfort of the study intervention between the 3 groups	Patient reported on 1-5 Likert scale	Immediately before intervention, at 1-hour mark of the intervention, immediately following the intervention, and 1 hour after the intervention ends.
Secondary	Comparison of the proportion of subjects within each group who are hospitalized.	Determine whether the patient is discharged home vs. placed in observation/admission status after completion of emergency department care.	Day of enrollment
Secondary	Compare the total duration of Emergency Department treatment measured from the time of delivery of the first intervention to the time of disposition.	Measured in hours/minutes	Day of enrollment
Secondary	Comparison of the quantity opioids, converted to morphine milligram equivalents, administered while under the care of the ED clinical team.	Measured in morphine milligram equivalents	Day of enrollment
Secondary	Comparison of the change in pain scores between the 3 groups at one hour after study intervention begins.	Patient reported on 0-10 scale	A single time point 1 hour after the study intervention begins.
Secondary	Comparison of the change in pain scores between the 3 groups at completion of the study intervention.	Patient reported on 0-10 scale	A single time point at the completion of the study intervention.